S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.15 (-5.55%)
BABA   83.89 (-0.59%)
AMD   68.02 (+0.12%)
T   15.60 (-2.07%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.31 (-1.60%)
GE   66.51 (-1.38%)
DIS   100.27 (-0.53%)
AMC   7.35 (+0.27%)
PYPL   94.32 (+0.52%)
PFE   43.45 (-1.52%)
NFLX   235.23 (-0.63%)
S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.15 (-5.55%)
BABA   83.89 (-0.59%)
AMD   68.02 (+0.12%)
T   15.60 (-2.07%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.31 (-1.60%)
GE   66.51 (-1.38%)
DIS   100.27 (-0.53%)
AMC   7.35 (+0.27%)
PYPL   94.32 (+0.52%)
PFE   43.45 (-1.52%)
NFLX   235.23 (-0.63%)
S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.15 (-5.55%)
BABA   83.89 (-0.59%)
AMD   68.02 (+0.12%)
T   15.60 (-2.07%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.31 (-1.60%)
GE   66.51 (-1.38%)
DIS   100.27 (-0.53%)
AMC   7.35 (+0.27%)
PYPL   94.32 (+0.52%)
PFE   43.45 (-1.52%)
NFLX   235.23 (-0.63%)
S&P 500   3,758.54 (-0.65%)
DOW   30,084.84 (-0.62%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.15 (-5.55%)
BABA   83.89 (-0.59%)
AMD   68.02 (+0.12%)
T   15.60 (-2.07%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.31 (-1.60%)
GE   66.51 (-1.38%)
DIS   100.27 (-0.53%)
AMC   7.35 (+0.27%)
PYPL   94.32 (+0.52%)
PFE   43.45 (-1.52%)
NFLX   235.23 (-0.63%)
NASDAQ:MRNA

Moderna - MRNA Price Target & Analyst Ratings

$123.61
-2.01 (-1.60%)
(As of 10/6/2022 10:23 AM ET)
Add
Compare
Today's Range
$123.58
$127.56
50-Day Range
$118.07
$194.18
52-Week Range
$115.03
$376.65
Volume
30,640 shs
Average Volume
4.99 million shs
Market Capitalization
$49.17 billion
P/E Ratio
3.77
Dividend Yield
N/A
Price Target
$211.08

Moderna Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 12 Analyst Ratings

Consensus Analyst Price Target

$211.08
70.77% Upside
High Prediction$395.00
Average Prediction$211.08
Low Prediction$77.00
TypeCurrent
10/6/21 to 10/6/22
1 Month Ago
9/6/21 to 9/6/22
3 Months Ago
7/8/21 to 7/8/22
1 Year Ago
10/6/20 to 10/6/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$211.08$226.92$228.00$195.62
Predicted Upside70.77% Upside16.51% Upside19.62% Upside1.73% Upside
Get Moderna Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.


MRNA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Moderna Stock vs. The Competition

TypeModernaMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.68
2.49
Consensus RatingHoldBuyHold
Predicted Upside68.03% Upside1,080.38% Upside27.51% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
180
65.69%
Underperform Votes
94
34.31%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
853
68.40%
Avg. Underperform Votes
394
31.60%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/14/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$180.00 ➝ $150.00+14.24%
9/7/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$155.00 ➝ $165.00+22.53%
8/4/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$199.00 ➝ $197.00+3.66%
8/1/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform$70.00 ➝ $77.00-53.07%
5/17/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$348.00 ➝ $214.00+50.41%
2/25/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Yee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$200.00 ➝ $170.00+7.90%
2/25/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$404.00 ➝ $210.00+33.28%
2/1/2022Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral
1/21/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$221.00+31.92%
1/21/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$135.00 ➝ $180.00+7.45%
12/6/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$250.00-5.66%
11/8/2021Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$304.00+24.24%
11/5/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$395.00+39.07%
8/5/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
7/7/2021Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
4/16/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
2/26/2021Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$180.00 ➝ $205.00+31.52%
2/1/2021Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Equal Weight$129.00 ➝ $145.00-16.26%
11/17/2020BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$109.00+11.28%
8/6/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
7/27/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Welles Fitzpatrick
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$120.00+50.17%
5/11/2020Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$41.00 ➝ $68.00+14.77%
1/2/2020Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Edward Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$24.00+26.48%
(Data available from 10/6/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MRNA Price Target - Frequently Asked Questions

What is Moderna's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Moderna stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for MRNA. The average twelve-month price prediction for Moderna is $211.08 with a high price target of $395.00 and a low price target of $77.00. Learn more on MRNA's analyst rating history.

Do Wall Street analysts like Moderna more than its competitors?

Analysts like Moderna less than other Medical companies. The consensus rating for Moderna is Hold while the average consensus rating for medical companies is Buy. Learn more on how MRNA compares to other companies.

Do MarketBeat users like Moderna more than its competitors?

MarketBeat users like Moderna less than other Medical companies. 65.69% of MarketBeat users gave Moderna an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Is Moderna being upgraded by Wall Street analysts?

Over the previous 90 days, Moderna's stock had 1 upgrade by analysts.

Does Moderna's stock price have much upside?

According to analysts, Moderna's stock has a predicted upside of 12.18% based on their 12-month price targets.

What analysts cover Moderna?

Moderna has been rated by Argus, Deutsche Bank Aktiengesellschaft, Morgan Stanley, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:MRNA) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.